m+Medelevator.RU
← Поиск публикаций
Organic & biomolecular chemistry · 2025

Isolation and total synthesis of a cytotoxic polyketide lead from Aspergillus sp. YUD22001 associated with Panax notoginseng rhizosphere.

СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Zhang Yan, Li Hong-Tao, Geng Yan, Dong Hai-Xia, Xie Tian-Peng, Xia Dan-Dan, Lin Xing-Mi, Ma Ling, Yin Min, Zhou Hao, Ding Zhong-Tao

Аннотация

A chemical investigation of Aspergillus sp. YUD22001, a rhizosphere-derived fungus isolated from diseased Panax notoginseng roots, resulted in the discovery of two new polyketides, asperketones A (1) and B (2), alongside seven known secondary metabolites (3-9). The structures of these compounds were unambiguously determined through comprehensive spectroscopic analyses. Asperketone A (1) demonstrated broad-spectrum cytotoxicity against four human cancer cell lines with IC50 values ranging from 6.1 to 29.4 μM. Notably, it exhibited significantly greater potency than cisplatin against A549, SMMC-7721 and MDA-MB-231 cells, while displaying reduced cytotoxicity toward normal bronchial epithelial cells (BEAS-2B). In contrast, asperketone B, which bears a methyl acetate substituent instead of the butan-2-one chain, showed negligible activity (IC50 > 50 μM), underscoring the structural importance of the butan-2-one pharmacophore. Molecular docking implicated lactate dehydrogenase A (LDHA) as a potential target, with 1 forming key hydrogen bonds via its ketone carbonyl. A scalable total synthesis of 1 was achieved via a boronate-mediated coupling strategy, enabling gram-scale production. This study highlights the underexplored potential of rhizospheric fungi as sources of bioactive natural products and demonstrates the synergistic integration of natural product discovery, synthetic methodology, and computational biology for anticancer drug development.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты